Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7687794 | 1.00 | LSS (1.00) | LSSMEN1KMT2ALMNAMAPT | |
| Hydrochloric Acid SCHEMBL7687467 | 0.99 | LSS (0.98) | LSSMEN1KMT2ALMNAMAPT | |
| Fumaric Acid SCHEMBL7687490 | 0.94 | LSS (0.88) | LSS | |
| SCHEMBL17358774 | 0.87 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL7688275 | 0.87 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL7685531 | 0.85 | LSS (0.74) | LSSMEN1KMT2ALMNAMAPT | |
| SCHEMBL7681227 | 0.85 | LSS (0.73) | LSSMEN1KMT2ALMNAMAPT | |
| SCHEMBL7683282 | 0.84 | LSS (0.72) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL7685407 | 0.82 | LSS (0.90) | LSSMEN1KMT2A | |
| SCHEMBL7687943 | 0.81 | LSS (1.00) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2866810-B9 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | UNIV MISSOURI (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | ESRRA, ESRRB, ESRRG | LSS 276/4885MEN1 4535/4885KMT2A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.